Trial Review

Technical difficulties have been reported by some users of the search function and is being investigated by technical staff. Thank you for your patience and apologies for any inconvenience caused.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/ct2/show/NCT05208047




Registration number
NCT05208047
Ethics application status
Date submitted
23/12/2021
Date registered
26/01/2022
Date last updated
24/05/2024

Titles & IDs
Public title
(Peak) A Phase 3 Randomized Trial of CGT9486+Sunitinib vs. Sunitinib in Subjects With Gastrointestinal Stromal Tumors
Scientific title
A Phase 3 Randomized, Open-Label, Multicenter Clinical Study of CGT9486+Sunitinib vs. Sunitinib in Subjects With Locally Advanced, Unresectable, or Metastatic Gastrointestinal Stromal Tumors
Secondary ID [1] 0 0
CGT9486-21-301
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Advanced Gastrointestinal Stromal Tumors 0 0
Metastatic Cancer 0 0
Condition category
Condition code
Cancer 0 0 0 0
Stomach
Cancer 0 0 0 0
Bowel - Small bowel (duodenum and ileum)
Cancer 0 0 0 0
Bowel - Back passage (rectum) or large bowel (colon)

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - CGT9486 plus sunitinib
Treatment: Drugs - CGT9486
Treatment: Drugs - Sunitinib
Treatment: Drugs - Sunitinib

Experimental: Part 1a - CGT9486 plus sunitinib 37.5 mg QD

Experimental: Part 2 - Experimental Group - CGT9486 plus sunitinib 37.5 mg QD

Active Comparator: Part 2 - Control Group - sunitinib 37.5 mg QD

Experimental: Part 1b - DDI Cohort 1 - CGT9486 plus sunitinib 37.5 mg QD

Experimental: Part 1b - DDI Cohort 2 - sunitinib 37.5 mg QD plus CGT9486


Treatment: Drugs: CGT9486 plus sunitinib
Participants will receive both CGT9486 and sunitinib orally until study stopping rules are met.

Treatment: Drugs: CGT9486
Participants will receive CGT9486 until steady state then both CGT9486 and sunitinib orally until study stopping rules are met.

Treatment: Drugs: Sunitinib
Participants will receive sunitinib until steady state then both sunitinib and CGT9486 orally until study stopping rules are met.

Treatment: Drugs: Sunitinib
Participants will receive sunitinib orally until study stopping rules are met.
Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Part 1a - pharmacokinetics - Cmax
Timepoint [1] 0 0
16 days
Primary outcome [2] 0 0
Part 1a - pharmacokinetics - AUC
Timepoint [2] 0 0
16 days
Primary outcome [3] 0 0
Part 1b - pharmacokinetics - Cmax
Timepoint [3] 0 0
14 days
Primary outcome [4] 0 0
Part 1b - pharmacokinetics - AUC
Timepoint [4] 0 0
14 days
Primary outcome [5] 0 0
Part 1b - pharmacokinetics - Tmax
Timepoint [5] 0 0
14 days
Primary outcome [6] 0 0
Part 2 - Progression Free Survival (PFS)
Timepoint [6] 0 0
Approximately 48 months
Secondary outcome [1] 0 0
All Study Parts - observing the safety of each treatment regimen.
Timepoint [1] 0 0
Approximately 48 months
Secondary outcome [2] 0 0
All Study Parts - observing the safety of each treatment regimen.
Timepoint [2] 0 0
Approximately 48 months
Secondary outcome [3] 0 0
All Study Parts - observing the safety of each treatment regimen.
Timepoint [3] 0 0
Approximately 48 months
Secondary outcome [4] 0 0
All Study Parts - observing the safety of each treatment regimen.
Timepoint [4] 0 0
Approximately 48 months
Secondary outcome [5] 0 0
All Study Parts - Overall Survival (OS)
Timepoint [5] 0 0
Approximately 48 months
Secondary outcome [6] 0 0
All Study Parts - Objective Response Rate (ORR)
Timepoint [6] 0 0
Approximately 48 months
Secondary outcome [7] 0 0
All Study Parts - Disease Control Rate (DCR)
Timepoint [7] 0 0
Approximately 48 months
Secondary outcome [8] 0 0
All Study Parts - Time to response (TTR)
Timepoint [8] 0 0
Approximately 48 months
Secondary outcome [9] 0 0
All Study Parts - Duration of Response (DOR)
Timepoint [9] 0 0
Approximately 48 months
Secondary outcome [10] 0 0
Part 2 Only - European Organisation for Research and Treatment of Cancer Quality of Life (EORTC-QLQ-30)
Timepoint [10] 0 0
Approximately 48 months

Eligibility
Key inclusion criteria
Key

1. Histologically confirmed locally advanced, metastatic, and/or unresectable GIST.
Molecular pathology report must be available for Part 2; if molecular pathology report
is unavailable or inadequate, an archival or fresh tumor tissue sample will be
required to evaluate mutational status prior to randomization.

2. Documented disease progression on or intolerance to imatinib

3. Subjects must have received the following treatment:

- Part 1a: Treatment with =1 prior lines of therapy for GIST

- Part 1b: Treatment with =2 prior TKI for GISTs

- Part 2: Prior treatment with imatinib only

4. Have at least 1 measurable lesion according to mRECIST v1.1

5. ECOG - 0 to 2

6. Have clinically acceptable local laboratory screening results (clinical chemistry and
hematology) within certain limits

Key
Minimum age
18 Years
Maximum age
No limit
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
1. Known PDGFR driving mutations or known succinate dehydrogenase deficiency

2. Clinically significant cardiac disease

3. Major surgeries (eg, abdominal laparotomy) within 4 weeks of the first dose of study
drug

4. Gastrointestinal abnormalities including, but not limited to, significant nausea and
vomiting, malabsorption, external biliary shunt, or significant bowel resection that
would preclude adequate absorption

5. Any active bleeding excluding hemorrhoidal or gum bleeding

6. Seropositive for HIV 1 or 2, or positive for hepatitis B surface antigen or hepatitis
C virus (HCV) antibody.

7. Active, uncontrolled, systemic bacterial, fungal, or viral infections at Screening

8. Received strong CYP3A4 inhibitors or inducers

9. Received sunitinib within 3 weeks (Part 1a, Part 1b)

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Parallel
Other design features
Phase
Phase 3
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Recruiting
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
14/04/2022
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
1/09/2026
Actual
Sample size
Target
426
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
WA
Recruitment hospital [1] 0 0
Sir Charles Gairdner Hospital - Nedlands
Recruitment hospital [2] 0 0
Bankstown-Lidcombe Hospital - Bankstown
Recruitment postcode(s) [1] 0 0
6009 - Nedlands
Recruitment postcode(s) [2] 0 0
2200 - Bankstown
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
Alabama
Country [2] 0 0
United States of America
State/province [2] 0 0
Arizona
Country [3] 0 0
United States of America
State/province [3] 0 0
California
Country [4] 0 0
United States of America
State/province [4] 0 0
Colorado
Country [5] 0 0
United States of America
State/province [5] 0 0
District of Columbia
Country [6] 0 0
United States of America
State/province [6] 0 0
Florida
Country [7] 0 0
United States of America
State/province [7] 0 0
Illinois
Country [8] 0 0
United States of America
State/province [8] 0 0
Iowa
Country [9] 0 0
United States of America
State/province [9] 0 0
Kansas
Country [10] 0 0
United States of America
State/province [10] 0 0
Massachusetts
Country [11] 0 0
United States of America
State/province [11] 0 0
Michigan
Country [12] 0 0
United States of America
State/province [12] 0 0
Minnesota
Country [13] 0 0
United States of America
State/province [13] 0 0
Missouri
Country [14] 0 0
United States of America
State/province [14] 0 0
Nebraska
Country [15] 0 0
United States of America
State/province [15] 0 0
New York
Country [16] 0 0
United States of America
State/province [16] 0 0
North Carolina
Country [17] 0 0
United States of America
State/province [17] 0 0
Ohio
Country [18] 0 0
United States of America
State/province [18] 0 0
Oregon
Country [19] 0 0
United States of America
State/province [19] 0 0
Pennsylvania
Country [20] 0 0
United States of America
State/province [20] 0 0
Tennessee
Country [21] 0 0
United States of America
State/province [21] 0 0
Texas
Country [22] 0 0
United States of America
State/province [22] 0 0
Washington
Country [23] 0 0
United States of America
State/province [23] 0 0
Wisconsin
Country [24] 0 0
Argentina
State/province [24] 0 0
Buenos Aires
Country [25] 0 0
Argentina
State/province [25] 0 0
Córdoba
Country [26] 0 0
Brazil
State/province [26] 0 0
Campinas
Country [27] 0 0
Brazil
State/province [27] 0 0
Rio De Janeiro
Country [28] 0 0
Brazil
State/province [28] 0 0
São Paulo
Country [29] 0 0
Canada
State/province [29] 0 0
Alberta
Country [30] 0 0
Canada
State/province [30] 0 0
Ontario
Country [31] 0 0
Canada
State/province [31] 0 0
Calgary
Country [32] 0 0
Canada
State/province [32] 0 0
Montréal
Country [33] 0 0
Chile
State/province [33] 0 0
Santiago
Country [34] 0 0
Czechia
State/province [34] 0 0
Brno
Country [35] 0 0
Czechia
State/province [35] 0 0
Hradec Králové
Country [36] 0 0
Czechia
State/province [36] 0 0
Olomouc
Country [37] 0 0
Denmark
State/province [37] 0 0
Aarhus
Country [38] 0 0
France
State/province [38] 0 0
Bordeaux
Country [39] 0 0
France
State/province [39] 0 0
Lille
Country [40] 0 0
France
State/province [40] 0 0
Lyon
Country [41] 0 0
France
State/province [41] 0 0
Marseille
Country [42] 0 0
France
State/province [42] 0 0
Rennes
Country [43] 0 0
France
State/province [43] 0 0
Saint-Herblain
Country [44] 0 0
France
State/province [44] 0 0
Toulouse
Country [45] 0 0
France
State/province [45] 0 0
Villejuif
Country [46] 0 0
Germany
State/province [46] 0 0
Bad Saarow
Country [47] 0 0
Germany
State/province [47] 0 0
Berlin
Country [48] 0 0
Germany
State/province [48] 0 0
Essen
Country [49] 0 0
Germany
State/province [49] 0 0
Hannover
Country [50] 0 0
Germany
State/province [50] 0 0
Mannheim
Country [51] 0 0
Hong Kong
State/province [51] 0 0
Central
Country [52] 0 0
Hong Kong
State/province [52] 0 0
Jordon
Country [53] 0 0
Hong Kong
State/province [53] 0 0
Sha Tin
Country [54] 0 0
Hungary
State/province [54] 0 0
Debrecen
Country [55] 0 0
Italy
State/province [55] 0 0
Aviano
Country [56] 0 0
Italy
State/province [56] 0 0
Bologna
Country [57] 0 0
Italy
State/province [57] 0 0
Brescia
Country [58] 0 0
Italy
State/province [58] 0 0
Candiolo
Country [59] 0 0
Italy
State/province [59] 0 0
Firenze
Country [60] 0 0
Italy
State/province [60] 0 0
Meldola
Country [61] 0 0
Italy
State/province [61] 0 0
Milano
Country [62] 0 0
Italy
State/province [62] 0 0
Palermo
Country [63] 0 0
Italy
State/province [63] 0 0
Roma
Country [64] 0 0
Italy
State/province [64] 0 0
Rozzano
Country [65] 0 0
Italy
State/province [65] 0 0
Verona
Country [66] 0 0
Korea, Republic of
State/province [66] 0 0
Gyeonggi-do
Country [67] 0 0
Korea, Republic of
State/province [67] 0 0
Seoul
Country [68] 0 0
Mexico
State/province [68] 0 0
Aguascalientes
Country [69] 0 0
Mexico
State/province [69] 0 0
Monterrey
Country [70] 0 0
Mexico
State/province [70] 0 0
Oaxaca
Country [71] 0 0
Netherlands
State/province [71] 0 0
Amsterdam
Country [72] 0 0
Netherlands
State/province [72] 0 0
Groningen
Country [73] 0 0
Netherlands
State/province [73] 0 0
Nijmegen
Country [74] 0 0
Netherlands
State/province [74] 0 0
Rotterdam
Country [75] 0 0
Norway
State/province [75] 0 0
Bergen
Country [76] 0 0
Norway
State/province [76] 0 0
Oslo
Country [77] 0 0
Poland
State/province [77] 0 0
Brzozów
Country [78] 0 0
Poland
State/province [78] 0 0
Bydgoszcz
Country [79] 0 0
Poland
State/province [79] 0 0
Gliwice
Country [80] 0 0
Poland
State/province [80] 0 0
Warsaw
Country [81] 0 0
Spain
State/province [81] 0 0
Barcelona
Country [82] 0 0
Spain
State/province [82] 0 0
El Palmar
Country [83] 0 0
Spain
State/province [83] 0 0
Madrid
Country [84] 0 0
Spain
State/province [84] 0 0
Santiago De Compostela
Country [85] 0 0
Spain
State/province [85] 0 0
Sevilla
Country [86] 0 0
Spain
State/province [86] 0 0
Zaragoza
Country [87] 0 0
Sweden
State/province [87] 0 0
Lund
Country [88] 0 0
Sweden
State/province [88] 0 0
Solna
Country [89] 0 0
Taiwan
State/province [89] 0 0
Kaohsiung
Country [90] 0 0
Taiwan
State/province [90] 0 0
New Taipei City
Country [91] 0 0
Taiwan
State/province [91] 0 0
Taichung
Country [92] 0 0
Taiwan
State/province [92] 0 0
Taipei
Country [93] 0 0
Taiwan
State/province [93] 0 0
Taoyuan
Country [94] 0 0
United Kingdom
State/province [94] 0 0
Cambridge
Country [95] 0 0
United Kingdom
State/province [95] 0 0
Glasgow
Country [96] 0 0
United Kingdom
State/province [96] 0 0
London
Country [97] 0 0
United Kingdom
State/province [97] 0 0
Manchester
Country [98] 0 0
United Kingdom
State/province [98] 0 0
Sheffield

Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Name
Cogent Biosciences, Inc.
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
This is a Phase 3, open-label, international, multicenter study of CGT9486 in combination
with sunitinib. This is a multi-part study that will enroll approximately 426 patients. Part
1 consists of two evaluations: 1) confirming the dose of an updated formulation of CGT9486 to
be used in subsequent parts in approximately 20 patients who have received at least one prior
line of therapy for GIST and 2) evaluating for drug-drug interactions between CGT9486 and
sunitinib in approximately 18 patients who have received at least two prior tyrosine kinase
inhibitors (TKIs) for GISTs. The second part of the study will enroll approximately 388
patients who are intolerant to, or who failed prior treatment with imatinib only and will
compare the efficacy of CGT9486 plus sunitinib to sunitinib alone with patients being
randomized in a 1:1 manner.
Trial website
https://clinicaltrials.gov/ct2/show/NCT05208047
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Jessica Sachs, MD
Address 0 0
Cogent Biosciences
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Cogent Biosciences
Address 0 0
Country 0 0
Phone 0 0
617-945-5576
Fax 0 0
Email 0 0
peakinfo@cogentbio.com
Contact person for scientific queries



Summary Results

For IPD and results data, please see https://clinicaltrials.gov/ct2/show/NCT05208047